Literature DB >> 28480210

Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.

Monica Venere1.   

Abstract

Entities:  

Year:  2017        PMID： 28480210      PMCID： PMC5401662          DOI： 10.21037/atm.2017.03.46

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  15 in total

1.  Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.

Authors:  Alexander V Gasparian; Catherine A Burkhart; Andrei A Purmal; Leonid Brodsky; Mahadeb Pal; Madhi Saranadasa; Dmitry A Bosykh; Mairead Commane; Olga A Guryanova; Srabani Pal; Alfiya Safina; Sergey Sviridov; Igor E Koman; Jean Veith; Anton A Komar; Andrei V Gudkov; Katerina V Gurova
Journal:  Sci Transl Med       Date:  2011-08-10       Impact factor: 17.956

2.  FACT-mediated exchange of histone variant H2AX regulated by phosphorylation of H2AX and ADP-ribosylation of Spt16.

Authors:  Kyu Heo; Hyunjung Kim; Si Ho Choi; Jongkyu Choi; Kyunghwan Kim; Jiafeng Gu; Michael R Lieber; Allen S Yang; Woojin An
Journal:  Mol Cell       Date:  2008-04-11       Impact factor: 17.970

3.  Histone chaperone FACT regulates homologous recombination by chromatin remodeling through interaction with RNF20.

Authors:  Douglas V Oliveira; Akihiro Kato; Kyosuke Nakamura; Tsuyoshi Ikura; Masahiro Okada; Junya Kobayashi; Hiromi Yanagihara; Yuichiro Saito; Hiroshi Tauchi; Kenshi Komatsu
Journal:  J Cell Sci       Date:  2013-12-19       Impact factor: 5.285

4.  Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.

Authors:  Josephine Kam Tai Dermawan; Masahiro Hitomi; Daniel J Silver; Qiulian Wu; Poorva Sandlesh; Andrew E Sloan; Andrei A Purmal; Katerina V Gurova; Jeremy N Rich; Justin D Lathia; George R Stark; Monica Venere
Journal:  Cancer Res       Date:  2016-02-26       Impact factor: 12.701

5.  The H2B ubiquitin ligase RNF40 cooperates with SUPT16H to induce dynamic changes in chromatin structure during DNA double-strand break repair.

Authors:  Vijayalakshmi Kari; Andrei Shchebet; Heinz Neumann; Steven A Johnsen
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

6.  Human neuroblastoma I-type cells are malignant neural crest stem cells.

Authors:  R A Ross; B A Spengler; C Domènech; M Porubcin; W J Rettig; J L Biedler
Journal:  Cell Growth Differ       Date:  1995-04

7.  Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

Authors:  Daniel R Carter; Jayne Murray; Belamy B Cheung; Laura Gamble; Jessica Koach; Joanna Tsang; Selina Sutton; Heyam Kalla; Sarah Syed; Andrew J Gifford; Natalia Issaeva; Asel Biktasova; Bernard Atmadibrata; Yuting Sun; Nicolas Sokolowski; Dora Ling; Patrick Y Kim; Hannah Webber; Ashleigh Clark; Michelle Ruhle; Bing Liu; André Oberthuer; Matthias Fischer; Jennifer Byrne; Federica Saletta; Le Myo Thwe; Andrei Purmal; Gary Haderski; Catherine Burkhart; Frank Speleman; Katleen De Preter; Anneleen Beckers; David S Ziegler; Tao Liu; Katerina V Gurova; Andrei V Gudkov; Murray D Norris; Michelle Haber; Glenn M Marshall
Journal:  Sci Transl Med       Date:  2015-11-04       Impact factor: 17.956

8.  A distinct gene expression signature characterizes human neuroblastoma cancer stem cells.

Authors:  Robert A Ross; Jeanette D Walton; Dan Han; Hong-Fen Guo; Nai-Kong V Cheung
Journal:  Stem Cell Res       Date:  2015-08-20       Impact factor: 2.020

9.  Enhanced chromatin dynamics by FACT promotes transcriptional restart after UV-induced DNA damage.

Authors:  Christoffel Dinant; Giannis Ampatziadis-Michailidis; Hannes Lans; Maria Tresini; Anna Lagarou; Malgorzata Grosbart; Arjan F Theil; Wiggert A van Cappellen; Hiroshi Kimura; Jiri Bartek; Maria Fousteri; Adriaan B Houtsmuller; Wim Vermeulen; Jurgen A Marteijn
Journal:  Mol Cell       Date:  2013-08-22       Impact factor: 17.970

10.  Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.

Authors:  Catherine Burkhart; Daria Fleyshman; Rachael Kohrn; Mairead Commane; Jennifer Garrigan; Vadim Kurbatov; Ilya Toshkov; Rajesh Ramachandran; Laura Martello; Katerina V Gurova
Journal:  Oncotarget       Date:  2014-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.